Fenebrutinib is a medication being studied for its potential to treat primary progressive multiple sclerosis (PPMS). It works by targeting specific proteins in the body that are involved in the immune response, which may help reduce inflammation and slow the progression of the disease.

Ocrelizumab is an existing treatment for primary progressive multiple sclerosis. It is a type of medication known as a monoclonal antibody, which targets and reduces certain immune cells that are believed to contribute to the damage of nerve cells in multiple sclerosis. This can help slow the progression of the disease and manage symptoms.

Primary Progressive Multiple Sclerosis – This is a form of multiple sclerosis characterized by a gradual worsening of neurological function from the onset of symptoms, without early relapses or remissions. It primarily affects the spinal cord and brain, leading to increasing disability over time. Symptoms may include problems with walking, muscle stiffness, and weakness. Unlike other forms of multiple sclerosis, this type does not have periods of recovery, making the progression more continuous. The disease can vary greatly in its impact, with some individuals experiencing more severe symptoms than others. It is a chronic condition that affects the central nervous system, leading to a range of physical and cognitive challenges.